Prognosis
Gilead Gets an Upgrade With Street Mulling Remdesivir Profit
Gilead headquarters in Foster City, California.
Photographer: David Paul Morris/BloombergThis article is for subscribers only.
The latest look at Gilead Sciences Inc.’s treatment for Covid-19 has Wall Street analysts contemplating profit, some for the first time.
After initial donations run out, Gilead could be making commercial revenue from remdesivir as soon as the third quarter, SunTrust analyst Robyn Karnauskas said after speaking to management including the biotech’s chief financial officer.